Capricor Therapeutics Shares Rise Following JonesTrading Upgrade Ahead of FDA Decision
Shares of Capricor Therapeutics (CAPR) saw a significant uptick on Wednesday following an upgrade by JonesTrading, which moved the biopharmaceutical company from 'Hold' to 'Buy.' The positive momentum is driven by investor anticipation surrounding the regulatory status of the company's lead asset, Deramiocel. The market is closely watching for a decision from the U.S. Food and Drug Administration (FDA) regarding the approval of Deramiocel, which is currently scheduled for November 22. This follows a previous extension by the regulator in August, heightening the importance of the upcoming deadline for the company's valuation.
Tickers: $CAPR
Topics: Biotechnology FDA Approval Stock Upgrade
Read the full article at Seeking Alpha
Part of the story Capricor Therapeutics shares rise as FDA decision nears (3 articles)